written like an advertisement . please help improve it by removing promotional content and inappropriate external links and by adding encyclopedic content written from a neutral point of view . august 2015 learn how and when to remove this template message wuxi pharmatech cayman inc. type public traded as nyse wx 1 industry contract research organizations pharmaceutical biopharmaceutical medical devices founded 2000 ipo date august 9 2007 headquarters shanghai china ; facilities in china and usa key people chairman and ceo ge li phd products laboratory services synthetic chemistry small molecule drug discovery dmpk adme drug safety evaluation bioanalytical services gene sequencing clinical trial services biologics drug discovery and development services biologics safety testing medical device safety testing manufacturing services small molecule api and advanced intermediate manufacturing biologics drug substance and drug product manufacturing cell banking and cellular therapeutics revenue usd499 .9 million 2010 net income usd 86.6 million 2010 number of employees 6 817 2012 6 273 in china 544 in usa 2 website official website wuxi pharmatech pronounced woo shee is a research and development r & d services company headquartered in shanghai with operations in china and the united states . the company uses an open access technology platform designed to enable efficient development of medicines for customers . wuxi acts as a contract researcher for most of the world s largest pharmaceutical biotech and medical device companies and many smaller companies . as of april 2013 the company had more than 1 600 customers . 2 contents 1 history 2 company segments 3 financials 4 references 5 external links history edit wuxi s founder dr ge li earned his doctorate in organic chemistry from columbia university and was a founding scientist at pharmacopeia inc. of princeton new jersey then returned to china to found wuxi pharmatech in shanghai in december 2000 . wuxi established services in synthetic chemistry in 2001 manufacturing process development in 2003 research manufacturing in 2004 bioanalytical services in 2005 service biology in 2006 and toxicology and formulation in 2007 . on december 14 2006 wuxi pharmatech announced that it was named 173rd on the deloitte technology fast 500 asia pacific 2006 ranking . 3 the company opened chemistry facilities in tianjin in 2007 . in 2008 wuxi pharmatech acquired apptec laboratory services inc. a us based company founded in 2001 with expertise in medical device and biologics testing and with facilities in st. paul mn ; philadelphia pa ; and atlanta ga. wuxi opened a toxicology facility in suzhou in 2009 . 2 wuxi opened a large scale manufacturing facility in jinshan in 2010 . the company began a biologics discovery development and manufacturing operation in shanghai and wuxi city in 2011 . at the same year wuxi acquired medkey a china based clinical research company and abgent a san diego company and one of the world s largest manufacturers of antibodies for biological research and drug discovery . in 2012 wuxi opened a chemistry facility in wuhan and a gmp biologics drug substance facility in wuxi city . that year wuxi also entered into a joint venture with medimmune the biologics arm of astrazeneca to co develop medi5117 an anti il6 antibody for rheumatoid arthritis for the chinese market . in 2013 wuxi formed a joint venture with the global clinical contract research organization pra international now called pra health sciences to build a clinical research business in china . company segments edit the company has two segments laboratory services and manufacturing services . laboratory services represent discovery and development services for pharmaceuticals development and testing services for biotherapeutics and medical devices and comprehensive toxicology services . the laboratory services segment generated 77 % of total company revenues in 2012 . synthetic chemistry and medicinal chemistry generate the largest portions of laboratory services revenues . since 2004 the company has offered manufacturing services for active pharmaceutical ingredients apis used in preclinical and clinical research . in 2011 wuxi began commercial manufacturing of advanced intermediates for the hepatitis c drug incivek telaprevir for vertex pharmaceuticals . as of 2013 the company subsidiary sta pharmaceutical manufactures advanced intermediates for six products . the manufacturing services segment generated 23 % of total company revenues in 2012 . 2 financials edit wuxi pharmatech has been listed on the new york stock exchange since august 9 2007 and its american depositary shares trade under the symbol wx . the equity market capitalization of wuxi was approximately 1.4 billion as of june 2013 . 4 total net revenue in the first quarter of 2013 was 131.9 million up 12 % year over year gross profit was 47.4 million up 13 % operating income was 23.0 million up 11 % net income was 21.7 million up 3 % and diluted eps was .30 up 7 % . 5 references edit a b http www.nyse.com about listed lcddata.html ticker wx a b c d wuxi pharmatech 17 april 2013 . wuxi pharmatech cayman inc. form 20 f annual and transition report of foreign private issuers . thomson reuters . wuxi pharmatechlisted among asia s fastest growing companies third year running . a b wuxi pharmatech announces fourth quarter and full year 2012 results a b wuxi pharmatech announces first quarter 2013 external links edit official website retrieved from https en.wikipedia.org w index.php title wuxi pharmatech & oldid 742495598 categories companies based in shanghaipharmaceutical companies of chinacompanies listed on the new york stock exchangepharmaceutical companies established in 2000contract research organizationsmultinational companieslife sciences industrychinese brandschinese companies established in 2000hidden categories articles with a promotional tone from august 2015all articles with a promotional tone navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 4 october 2016 at 02 01 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view